Literature DB >> 10383541

Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily.

C M Kirkpatrick1, S B Duffull, E J Begg.   

Abstract

AIMS: 1. To determine the population pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. 2. To see if current starting doses for once daily aminoglycoside dosing are appropriate. 3. To test whether calculating creatinine clearance using an adjusted Cockcroft and Gault method (CLCr,adjusted ) was a better predictor of gentamicin clearance than the standard Cockcroft and Gault method (CLCr,unadjusted ).
METHODS: Nine hundred and fifty-seven patients were dose-individualized for gentamicin using SeBA-GEN, a Bayesian dosing method. This method returns estimates of the values of gentamicin CL and V d from which the 24 h AUC can be estimated. The goal of therapy was to attain an AUC of 70-100 mg l-1 h depending on the severity of the infection. The population was divided into four groups of differing renal function. Linear regression analysis was performed to determine the relationship between V d and various indices of weight, and gentamicin CL and either CLCr,adjusted or CLCr,unadjusted.
RESULTS: The mean V d (+/-s. d.) and CL (+/-s.d.) of gentamicin in our total population were 17.4 (+/-4.1) l and 4.0 (+/-1.8) l h-1, respectively. There was a decrease in V d with reducing renal function when comparing patients with normal renal function and patients with poor renal function. The lower of total body weight (TBW) and lean body weight (LBW), termed dosing weight (DWT), was a slightly better predictor of V d (r2=0.28) than either TBW (r2=0.21) or LBW (r2=0.21). CLCr,adjusted (r2=0.80) was a better predictor of gentamicin CL than CLCr, unadjusted (r2=0.57).
CONCLUSIONS: The mean population values of V d and CL of gentamicin dosed once daily are similar to those described by others in relation to multiple daily dosing. Given that previous methods have been based on population values of V d and CL from multiple daily dosing, the currently recommended starting doses for once daily aminoglycoside dosing would seem appropriate. The V d reduced with decreasing renal function, with a maximum of 23% difference between patients with normal and poor renal function. The Cockcroft and Gault method of calculating creatinine clearance does not appear to perform well at low values of serum creatinine concentration. An adjustment of the Cockcroft and Gault method is proposed to allow for this.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10383541      PMCID: PMC2014263          DOI: 10.1046/j.1365-2125.1999.00938.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  Prediction of creatinine clearance from serum creatinine.

Authors:  D W Cockcroft; M H Gault
Journal:  Nephron       Date:  1976       Impact factor: 2.847

Review 2.  Single daily dosing of aminoglycosides in immunocompromised adults: a systematic review.

Authors:  R Hatala; T T Dinh; D J Cook
Journal:  Clin Infect Dis       Date:  1997-05       Impact factor: 9.079

3.  Role of pharmacokinetics in drug dosage adjustment. I. Pharmacologic effect kinetics and apparent volume of distribution of digoxin.

Authors:  R H Reuning; R A Sams; R E Notari
Journal:  J Clin Pharmacol New Drugs       Date:  1973-04

4.  A Bayesian feedback method of aminoglycoside dosing.

Authors:  M E Burton; D C Brater; P S Chen; R B Day; P J Huber; M R Vasko
Journal:  Clin Pharmacol Ther       Date:  1985-03       Impact factor: 6.875

5.  Once-daily dosing of gentamicin: experience with therapeutic drug monitoring and Bayesian pharmacokinetics.

Authors:  U Klotz; A Godel
Journal:  Ther Drug Monit       Date:  1994-10       Impact factor: 3.681

6.  Influence of weight on aminoglycoside pharmacokinetics in normal weight and morbidly obese patients.

Authors:  L A Bauer; W A Edwards; E P Dellinger; D A Simonowitz
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

7.  Once versus thrice daily gentamicin in patients with serious infections.

Authors:  J M Prins; H R Büller; E J Kuijper; R A Tange; P Speelman
Journal:  Lancet       Date:  1993-02-06       Impact factor: 79.321

Review 8.  Aminoglycoside pharmacokinetics: volume of distribution in specific adult patient subgroups.

Authors:  W E Dager
Journal:  Ann Pharmacother       Date:  1994 Jul-Aug       Impact factor: 3.154

9.  Prediction equation estimates of creatinine clearance in the intensive care unit.

Authors:  G R Pesola; I Akhavan; A Madu; N K Shah; G C Carlon
Journal:  Intensive Care Med       Date:  1993       Impact factor: 17.440

10.  Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.

Authors:  D P Nicolau; C D Freeman; P P Belliveau; C H Nightingale; J W Ross; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1995-03       Impact factor: 5.191

View more
  35 in total

1.  Aminoglycoside dosage regimens after therapeutic drug monitoring.

Authors:  Carl M J Kirkpatrick; Evan J Begg; Murray L Barclay; Stephen B Duffull
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

2.  Clinical decision support implemented with academic detailing improves prescribing of key renally cleared drugs in the hospital setting.

Authors:  Gregory W Roberts; Christopher J Farmer; Philip C Cheney; Stephen M Govis; Thomas W Belcher; Scott A Walsh; Robert J Adams
Journal:  J Am Med Inform Assoc       Date:  2010 May-Jun       Impact factor: 4.497

3.  Therapeutic drug monitoring of antimicrobials.

Authors:  Jason A Roberts; Ross Norris; David L Paterson; Jennifer H Martin
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

4.  Comparison of gentamicin dose estimates derived from manual calculations, the Australian 'Therapeutic Guidelines: Antibiotic' nomogram and the SeBA-GEN and DoseCalc software programs.

Authors:  Mitali Mohan; Kevin T Batty; Jennifer A Cooper; Richard E Wojnar-Horton; Kenneth F Ilett
Journal:  Br J Clin Pharmacol       Date:  2004-11       Impact factor: 4.335

5.  Assessment of renal function in clinical practice at the bedside of burn patients.

Authors:  J M Conil; B Georges; O Fourcade; T Seguin; M Lavit; K Samii; G Houin; I Tack; S Saivin
Journal:  Br J Clin Pharmacol       Date:  2006-12-07       Impact factor: 4.335

6.  Population pharmacokinetic modelling of gentamicin and vancomycin in patients with unstable renal function following cardiothoracic surgery.

Authors:  Christine E Staatz; Colette Byrne; Alison H Thomson
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

7.  Drug therapy in kidney disease.

Authors:  Jeffrey K Aronson
Journal:  Br J Clin Pharmacol       Date:  2007-05       Impact factor: 4.335

8.  Target concentration intervention is needed for tobramycin dosing in paediatric patients with cystic fibrosis--a population pharmacokinetic study.

Authors:  Stefanie Hennig; Ross Norris; Carl M J Kirkpatrick
Journal:  Br J Clin Pharmacol       Date:  2007-11-08       Impact factor: 4.335

9.  Bayesian Estimation of Tobramycin Exposure in Patients with Cystic Fibrosis.

Authors:  Michael A Barras; David Serisier; Stefanie Hennig; Katrina Jess; Ross L G Norris
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

10.  The impact of frailty on pharmacokinetics in older people: using gentamicin population pharmacokinetic modeling to investigate changes in renal drug clearance by glomerular filtration.

Authors:  Claire Johnston; Sarah N Hilmer; Andrew J McLachlan; Slade T Matthews; Peter R Carroll; Carl M Kirkpatrick
Journal:  Eur J Clin Pharmacol       Date:  2014-02-14       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.